Good MorningEquity markets started the holiday-shortened week on solid footing, advancing incrementally to hover near record highs. The move was partly supported by President-elect Trump's pick of Scott Bessent for Treasury Secretary. The market favors the pick because his economic views will temper Donald Trump's more aggressive stance and reduce the risk of inflation accelerating.
The hurdle for markets this week is Wednesday. The economic calendar contains market-moving reports, including the Fed minutes and PCE price index. The PCE price index is expected to reveal inflation accelerating at the headline and core levels, contradicting the trend that led the FOMC to cut rates in September. This will be the second month inflation has increased since the Fed first cut rates, and it will likely keep them from cutting again in December, news that may keep the S&P 500 from hitting another new high this year. Featured: Trump won. Buy this coin now. (Weiss Ratings) 
|
Markets | | |
Retail investors often feel on the outside of the stock market since information can often be hard to access and digest when the factors and trends to be identified aren’t too clear-cut. This is why looking at Wall Street analyst actions can be an important checklist for retail investors whe... Read the Full Story |
|
From Our PartnersNow is the time to consider a time-tested asset favored by conservative investors for navigating market volatility and building long-term security. Whether the results lean toward continuity or change, this asset remains a stable cornerstone for safeguarding wealth and driving growth.
By following the link, you're choosing to opt in to receive insightful updates from Wealth Creation Investing + 2 free bonus subscriptions! Your privacy is important to us. You can unsubscribe anytime. See our privacy policy for details. | | | | [Download the Free Guide Now] to explore the potential of this strategy and discover what may be missing from your financial plan. |
|
Stocks | | | U.S. stocks rose to records Tuesday after Donald Trump’s latest talk about tariffs created only some ripples on Wall Street, even if they could roil the global economy were they to take effect.The S&P 500 climbed 0.6% to top the all-time high it set a couple weeks ago. The Dow Jones Industrial... Read the Full Story |
|
Stocks | | | U.S. stocks rose Monday, with those benefiting the most from lower interest rates and a stronger economy leading the way.The S&P 500 climbed 0.3% to pull closer to its all-time high set two weeks ago. The Dow Jones Industrial Average added 440 points, or 1%, to its own record set on Friday, whil... Read the Full Story |
|
|
Markets | | |
With the Trump administration taking over in January 2025, there has been much speculation about forthcoming changes, trends, and themes. With Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk firmly embedded in Trump’s inner circle, there’s been speculation that self-driving or autonomous cars ... Read the Full Story |
|
Markets | | | Investor Warren Buffett renewed his Thanksgiving tradition of giving by handing out more than $1.1 billion of Berkshire Hathaway stock to four of his family's foundations Monday, and he offered new details about who will be handing out the rest of his fortune after his death Read the Full Story |
|
From Our PartnersWhile other cell phone carriers are always looking for ways to squeeze every last penny out of their customers, my company pays users for the 40 hours a week they are using smartphone apps, listening to music, and watching videos online with their phones.
And you can join us for just $0.26 per share. Plus, when you invest now, you can get up to 100% bonus shares! | | | | Let’s change the future of mobile together. |
|
Markets | | |
Following the 2024 U.S. election, there has been a great deal of speculation about how a second Trump administration will set policies that have an impact on the economy. Some have taken a strongly optimistic view of what's to come—a recent Goldman Sachs report suggested that the likelihood ... Read the Full Story |
|
Markets | | |
Abacus Life, Inc. (NASDAQ: ABL) is a global alternative asset manager specializing in a unique niche within the financial markets. The company acquires and manages life insurance policies.
The company's core mission is to generate financial returns for investors and educate consumers on the of... Read the Full Story |
|
Markets | | | Wall Street is betting corporate dealmaking could bounce back next year if the new Trump administration ushers in lower interest rates and looser regulatory scrutiny. The number of deals and their value are both below pre-pandemic levels. In the U.S., deal values fell 23% in 2023 from just before th... Read the Full Story |
|
Markets | | | Bath & Body Works fiscal third-quarter performance topped analysts' estimates thanks to strong sales, and the retailer boosted its full-year outlook.The owner of Victoria’s Secret, Bath & Body Works and other chain stores earned $106 million, or 49 cents per share, for the period. A year ear... Read the Full Story |
|
Markets | | |
Investing in companies in their first year of being publicly traded can be an exciting and perilous proposition. It may take time for enough information to come out about a new stock before the market can gather a strong sense of its actual value, leading to volatility. Shares can see large uptick... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. | Should I Buy Gilead Sciences Stock? GILD Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Sunday, June 01, 2025 at 6:29 PM.
Gilead Sciences Bull Case -
Recent analyst upgrades have significantly increased target prices, with some analysts setting targets as high as $140, indicating strong market confidence in the company's future performance.
-
The current stock price is around $110.55, which is considered attractive given the potential for growth based on recent positive analyst ratings.
-
Gilead Sciences, Inc. has a diverse portfolio of biopharmaceutical products addressing unmet medical needs, which can lead to sustained revenue growth.
-
With a majority of analysts rating the stock as a "buy" or "strong buy," there is a consensus that the company is well-positioned for future success.
-
Insider ownership, although small, indicates that company executives have a vested interest in the stock's performance, which can align their goals with those of shareholders.
Gilead Sciences Bear Case -
Insider selling of 50,929 shares worth over $5.6 million may raise concerns about the executives' confidence in the company's short-term prospects.
-
Despite recent upgrades, the stock has experienced fluctuations, which may indicate volatility and risk for potential investors.
-
Some analysts have issued hold ratings, suggesting that there may be uncertainty about the stock's immediate growth potential.
-
The biopharmaceutical industry is highly competitive, and Gilead Sciences, Inc. faces challenges from other companies developing similar therapies.
-
Market conditions can change rapidly, and external factors such as regulatory changes or economic downturns could negatively impact the company's performance.
| | View Today's Stock Pick |
|
